Aptamers to Tissue Factor Pathway Inhibitor and Their Use as Bleeding Disorder Therapeutics
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 2 of these applications claim priority to application 12/858,369, filed Aug 17, 2010. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 8,461,318 | Aptamers to Tissue Factor Pathway Inhibitor and Their Use as Bleeding Disorder Thereapeutics In force · Medium confidence | Baxalta GmbH and Baxalta Incorporated | In force | Medium confidence | ||
| US 8,252,913 | Aptamers to Tissue Factor Pathway Inhibitor and Their Use as Bleeding Disorder Therapeutics In force · High confidence | Takeda Pharmaceutical Company Limited | In force | High confidence | ||
| US 8,598,327 | Aptamers to Tissue Factor Pathway Inhibitor and Their Use as Bleeding Disorder Therapeutics In force · Medium confidence | Baxalta GmbH and Baxalta Incorporated | In force | Medium confidence |
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
2 of these are in force and held by Baxalta Incorporated.
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.